Reading — Test 20

Reading passage

The discovery of antibiotics in the twentieth century stands as one of medicine's most consequential achievements, yet the path from initial observation to widespread clinical use was neither swift nor straightforward. Prior to the 1930s, physicians possessed few effective tools against bacterial infection; even minor wounds could prove fatal once sepsis set in. The eventual harnessing of microbial chemistry to fight infection required decades of accumulated insight, chance observation, and painstaking refinement before it could be translated into a reliable therapy. The conventional narrative credits Alexander Fleming's 1928 observation of a mold contaminant, later identified as Penicillium notatum, growing on a culture plate of Staphylococcus bacteria. Fleming noticed that the bacterial colonies surrounding the mold had been destroyed, while colonies farther away remained unaffected. He hypothesized that the mold was secreting a substance lethal to the bacteria, which he named penicillin. Fleming published his findings in 1929, but he lacked the chemical expertise to isolate and stabilize the compound in a form suitable for treating patients. The mold's active ingredient proved notoriously unstable outside laboratory conditions, degrading before it could be purified in useful quantities. Consequently, Fleming's discovery languished for roughly a decade, cited occasionally in the scientific literature but never developed into a usable drug. This gap between observation and application illustrates a recurring pattern in the history of science: a discovery's significance is not always evident to its original observer, nor is recognition alone sufficient to yield practical benefit. The transformation of penicillin from laboratory curiosity to lifesaving medicine owed much to a team at Oxford University led by pathologist Howard Florey and biochemist Ernst Chain, who took up the problem in the late 1930s. Aware of Fleming's earlier work, Florey and Chain assembled a team of chemists and biologists to extract, purify, and concentrate the compound using freeze-drying and chromatographic techniques unavailable a decade earlier. Their efforts culminated in 1940, when they demonstrated that purified penicillin could cure infected mice, and in 1941, when a small quantity administered to a human patient produced a dramatic though ultimately incomplete recovery, since the limited supply ran out before the infection was fully cleared. This scarcity underscored an urgent practical obstacle: even a proven compound was worthless at scale without a means of mass production. Wartime conditions in Britain, where industrial resources were devoted to the military effort, made large-scale manufacturing difficult, so Florey traveled to the United States seeking manufacturers capable of fermenting the mold in the volumes required. American pharmaceutical companies, aided by government funding and a strain of Penicillium discovered on a moldy cantaloupe in Peoria, Illinois, that yielded far higher quantities of the compound than Fleming's original strain, achieved the industrial breakthrough that Britain alone could not. By 1944, production had scaled sufficiently to treat Allied soldiers wounded during the invasion of Normandy, and by the late 1940s, penicillin was widely available to civilian populations. Its success spurred a systematic search for other antibiotic-producing microorganisms, most notably by Selman Waksman, whose laboratory at Rutgers University screened soil samples for microbes capable of killing bacteria. This effort yielded streptomycin in 1943, the first effective treatment for tuberculosis, a disease that had defied earlier therapeutic approaches. Waksman's methodical screening process, in contrast to Fleming's serendipitous observation, established a deliberate research paradigm that pharmaceutical companies would replicate for decades, systematically testing soil-dwelling microorganisms for antimicrobial activity. The rapid proliferation of antibiotics in the mid-twentieth century created an impression, later shown to be overly optimistic, that infectious disease had been largely conquered. Fleming himself, in his 1945 Nobel Prize address, cautioned that the careless use of penicillin could allow bacteria to develop resistance, a warning that subsequent decades have borne out with troubling clarity. Bacteria reproduce rapidly and can acquire resistance genes through mutation or through the transfer of genetic material between different bacterial strains, meaning that any antibiotic, however effective initially, exerts selective pressure that favors resistant survivors. Overuse and misuse of antibiotics in both medicine and agriculture have accelerated this process, so that some infections once easily treated now resist multiple drug classes simultaneously. This unfolding challenge has transformed antibiotic discovery from a triumphant chapter in medical history into an ongoing and urgent endeavor, one in which researchers must continually search for new compounds merely to stay ahead of microbial adaptation.